logo
Hundreds of cystic fibrosis patients become eligible for ‘life-changing' therapy

Hundreds of cystic fibrosis patients become eligible for ‘life-changing' therapy

The National Institute for Health and Care Excellence (Nice) has given the green light for the NHS to give patients Alyftrek, a type of modulator therapy which works to tackle the underlying cause of cystic fibrosis (CF).
CF is caused by a faulty gene that affects the production of a protein called CFTR.
Modulator drugs work by helping to make the CFTR protein work effectively.
NHS officials said the treatments can 'transform' life expectancy and quality of life for patients.
There are a number of modulator therapies available but some patients with the rarest forms of the disease have been unable to access them until now.
Nice approved Alyftrek, which is known as a triple therapy, for patients aged six and over for the most common form of CF as an alternative to another treatment called Kaftrio.
And NHS England announced that the treatment would also be made available for children and adults with rare forms of cystic fibrosis, who have not previously been eligible for modulator therapy.
NHS England said the move allows patients with the rarest form of the disease to access the latest treatments, including Alyftrek and Kaftrio, for the first time.
It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy.
The new drug, also known as vanza triple, has been found to be as effective as current drug Kaftrio in clinical trials in improving and maintaining lung function in people with CF.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved the triple combination medicine – which is also known as deutivacaftor/tezacaftor/vanzacaftor – for use in the UK, for certain patients with CF over the age of six, in March.
Cystic fibrosis is a genetic condition that causes thick mucus to build up in the lungs and digestive system which leads to breathing difficulties and serious infections.
John Stewart, NHS England's director for specialised commissioning, said: 'This is a major leap forward for hundreds of patients living with the rarest forms of cystic fibrosis, offering fresh hope of a better quality of life.
'Access to a once-daily treatment at home can make an enormous difference to patients and their families – reducing the burden of hospital appointments and allowing children and young people to live more freely and independently.
'For those living with the rarest forms of the condition, this represents the very first time they will be able to access this new standard of care that has been so transformative for many since 2019.
'The rollout of this life-changing therapy demonstrates how the NHS continues to embrace innovation to deliver significant improvements in care for patients across the country at a fair price for the taxpayer.'
Helen Knight, director of medicines evaluation at Nice, said: 'CFTR modulators are already revolutionising the way cystic fibrosis is treated so we're pleased to be able to recommend Alyftrek, the latest of this type of treatment that has been shown to be effective, with significant benefits for people with the condition.'
David Ramsden, chief executive of the Cystic Fibrosis Trust, said: 'Today's announcements are another positive step in the journey to better treatments for everyone with cystic fibrosis – a lifelong, life-limiting condition without a cure.
'It's thanks to the incredible support and many years of campaigning of the CF community, and the work of all our partners, that modulator drugs are now a treatment option for thousands of people.'
Ludovic Fenaux, senior vice president at Vertex International, said the move 'represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Third of young people want fat jabs as demand spirals
Third of young people want fat jabs as demand spirals

Telegraph

timea few seconds ago

  • Telegraph

Third of young people want fat jabs as demand spirals

A third of young adults want to take fat jabs amid a surge in demand for the drugs, pharmacists have said. One in five people say they have tried to access a pharmacy weight-loss treatment in the past year but this figure is 35 per cent for those aged between 16 and 34. Pharmacists have raised the alarm that demand has far exceeded what can be clinically delivered. Concerns have also been raised that people could resort to looking for drugs such as Wegovy and Mounjaro from online sellers. Current guidelines state that patients being prescribed Mounjaro and Wegovy through pharmacies need a BMI of at least 35 and at least one weight-related comorbidity, such as diabetes, to be eligible. Wegovy can also be prescribed to patients with a BMI of 30–34 who meet the criteria for referral to specialist overweight and obesity management services. However, the NHS is only rolling out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities. It spent £269million on fat jabs in 2024-2025 and prescriptions doubled to almost three million a year. Mounjaro, regarded as the strongest jab and known as King Kong, has driven the spike in prescriptions with 1.1million given out in a year compared with 3,300 in the previous 12 months. The National Pharmacy Association (NPA), which represents about 6,000 pharmacies, surveyed 2,000 Britons and found evidence of demand beyond what the NHS can offer. It is now seeking greater clarity on how pharmacies will be further involved in the distribution of weight-loss medication, something laid out in the Government's recent 10 Year Health Plan. Olivier Picard, chairman of the NPA, said: 'Weight-loss jabs are one of the biggest drug innovations this century but growing demand highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight-loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from medication. 'We're also urging the Government to bring forward plans to include pharmacies in the rollout of their NHS weight-management programme. 'Pharmacists are experts in medication and many have extensive experience delivering weight-loss injections as part of a package of care including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS and help people make the best use of these powerful medicines,' he added

Prostate cancer checks soar after Sir Chris Hoy reveals diagnosis
Prostate cancer checks soar after Sir Chris Hoy reveals diagnosis

Telegraph

time30 minutes ago

  • Telegraph

Prostate cancer checks soar after Sir Chris Hoy reveals diagnosis

Thousands more men are having checks for prostate cancer since Sir Chris Hoy revealed he had been diagnosed with the disease and was terminally ill. The six-time Olympic cycling gold medallist was told in 2023 that he was terminally ill with cancer that originated in his prostate, and shared his diagnosis publicly last year. Despite a family history of prostate cancer – which also affected his father and grandfather – Sir Chris was never offered the PSA test that could have detected it. New NHS data show almost 5,000 extra men have been referred for urological cancer in the six months after Sir Chris, 49, spoke out, a trend described by experts as 'staggering'. The figures, from October 2024 to March 2025, show 138,734 men were given an urgent referral for urological cancers, with prostate cancer the main form of disease. This amounts to an extra 4,962 cases compared with the same six-month period in 2023-24. Separate data show a huge increase in the number of men with a family history of prostate cancer who have assessed their own risk. The number of men with such a history who have used an online risk checker to assess their chances of the disease rose by 77 per cent over the period. Telegraph launches screening campaign The findings have been released as The Telegraph launches a campaign calling for the introduction of targeted screening for prostate cancer. Men are not offered tests currently, even if they have a family history of the disease. Experts believe there is a growing case for targeted screening, meaning that PSA blood tests would be offered to those at heightened risk of the disease. Peter Kyle, the Science Secretary, hopes to harness AI and data to improve prostate cancer screening for high-risk men which factors in family history, genetics, demographics and other factors. Mr Kyle, writing in The Telegraph, said he hopes researchers can harness the vast amount of health data available to 'develop AI-powered tools that can predict cancer risk' to save thousands of lives a year. The UK National Screening Committee is currently considering whether to recommend the introduction of mass testing. 'I told my story to raise awareness' Sir Chris said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got. 'That's why I believe men at highest risk, for example men with a family history like me, or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. 'Then if there are any issues, they can get it treated it at an earlier stage. 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility.' The online risk checking tool, published by Prostate Cancer Research UK, asks men simple questions about their family history and ethnicity to determine risk levels, and gives advice about what help to seek. The charity found that the number of men undergoing the check rose by 45 per cent overall, when data from October 2024 to February 2025 was compared with the same period the year before. The sharpest increase by far came from men aged between 45 and 49, with a family history of the disease. In total 10,427 such men checked their risk, compared with 5,891 in the same period the previous years. In total there were 688,796 checks during the period, up from 473, 843 the year before.

Whitehaven plans for mental health hub at former bank
Whitehaven plans for mental health hub at former bank

BBC News

timean hour ago

  • BBC News

Whitehaven plans for mental health hub at former bank

Plans have been submitted to create a 24/7 mental health hub in a former bank building, as part of an NHS pilot Community Trust Limited has applied for permission to turn the former Halifax branch on King Street, Whitehaven, into the Hope Haven comes after NHS England announced the pilot to expand mental health services in the area and bring different services under one roof."The hub will provide drop-in support, 1:1 consultations, group therapy and sessions focused on physical health, fitness, health promotion and shared learning," planning documents submitted to Cumberland Council said. Various organisations would work from the hub including Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, mental health charities and organisations that can provide housing and employment Halifax branch shut in 2024 and although the building is not listed it sits within the Whitehaven town centre conservation documents said minimal alterations would be made to the outside of the building and any work would respect its "architectural character and historic value"."The proposed use seeks to revitalise the building, currently vacant and in a state of decline," they added. Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store